The importance of continued non-pharmaceutical interventions during the upcoming SARS-COV-2 vaccination campaign

In this communication we assess the potential benefit of SARS-COV-2 pandemic vaccination in the US and show how continued use of non-pharmaceutical interventions (NPIs) will be crucial during implementation.


Introduction
A global effort to develop vaccines against SARS-COV-2 began early in 2020, and several vaccine candidates have now reached final stages of the approval process. During mid-December the U.S. FDA is scheduled to discuss emergency use authorization (EUA) for two vaccines that have successfully concluded their phase 3 trials [1]. Vaccine distribution in the US will likely begin shortly after authorization. Both vaccines use mRNA technology and require two doses administered 3 and 4 weeks apart to reach the full 90-95% efficacy [2]. In light of limited supply, the Center for Disease Control and Prevention (CDC) has indicated it may prioritize vaccination for: 1) healthcare workers, 2) long-term care facility residents, 3) other essential workers and 4) people at higher risk for severe illness [3]. In this communication we assess the potential benefit of SARS-COV-2 pandemic vaccination in the US and show how continued use of NPIs will be crucial during implementation.

Methods
We simulated the progression of the pandemic at the US state level for different combinations of vaccination and other non-pharmaceutical interventions (NPIs), including school/business closure and social distancing. Projections were made with a SEIRV (Susceptible-Exposed-Infected-Recovered-Vaccinated) compartmental model. Simulations were generated for all 50 states with the population stratified by age and priority group. The model was parametrized using the age and population type-adjusted posterior distributions previously estimated with a nonstratified metapopulation model [4] (see Supplementary Material). Our vaccination timeline assumed 40 million doses available by the end of December and 10 million additional doses/week thereafter [5] ( Figure 1A) distributed to the population according to prioritization guidelines. Vaccination was administered regardless of previous history of infection and was assumed to be 90% effective preventing infection in susceptible individuals 1 week after the second dose. The seven vaccination and NPI scenarios are described in Table 1. We did not account for the possibility of reinfection in any of the simulations.

Results
Figures 1B-1D compare the proportion of US population infected (attack rate) for 7 different combinations of interventions and 3 different estimates of the basic reproductive number (R0) in the absence of NPIs. The baseline (NV) scenario with no vaccination and a complete relaxation of NPIs produces a 37-50% attack rate from December 4 through the end of September, depending on the basic reproductive number. With vaccination and the same complete relaxation of NPIs (Scenario V1), the attack rate would be reduced only 1-2%. In contrast, the attack rate is sizably reduced to 11%-15% when NPI controls are maintained until a substantial portion of the population has been vaccinated (Scenarios V3-V6).

Discussion
Our current estimate of the effective reproductive number (Rt= [0.8-1.2]) reflects not only the diminished susceptibility of the population due to accumulated natural immunity, but also the reduction in contact rates due to NPIs. However, NPIs are temporary mitigation measures, and their relaxation prior to comprehensive population-scale vaccination will re-inflate Rt and, in turn, the threshold for herd immunity. Overall, vaccination uptake over the next 9 months could prevent infection for up to 26% to 39% of the US population; however, this potential benefit depends strictly on maintaining NPIs during vaccine deployment: relaxing NPIs before attaining adequate vaccine coverage could result in tremendous loss of potentially averted cases, hospitalizations and mortality. In the limit scenario V1 in which all NPIs are immediately relaxed before the vaccination campaign, the averted infections are nominal. The findings based on this rapid analysis underscore the importance of maintaining NPIs throughout the upcoming SARS-CoV-2 vaccination campaign to maximize the public health benefit; more in-depth modeling will be performed as more information becomes available on vaccine availability. Public health messaging is critically needed to encourage continued compliance with NPI control measures in the coming months.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20248784 doi: medRxiv preprint  Figure 1A) Timeline of vaccination. The prioritization groups: healthcare workers (HC), other essential workers (EW) and 65+ with risk factors (65+PC) were vaccinated subsequently. We set 80%, 60% and 70% target coverages respectively for the 3 prioritization groups, corresponding to 15.5, 35.5 and 11.5 million individuals vaccinated (targets are marked on the y-axes). The vaccine was allocated to the 50 states in proportion to the percentage of residents belonging to each prioritization group. This vaccination schedule was used for simulating scenarios V1 to V6 of panels 1B, 1C and 1D. After the prioritization groups, we allocated vaccine to adults with preexisting condition (70% target coverage), then children and other adults (60% target coverage). See Table S3 for details on vaccine allocation. 1B,1C,1D) Distribution of the total attack rate (red lines are median values, blue boxes are the interquartile, and whiskers extend to the maximum and minimum values that are not outliers) in the US from December 4 th to the end of the pandemic for different estimates of R0 and different scenario combinations of vaccination and NPIs. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 26, 2020. ; Table 1: Scenarios for vaccination and NPIs.

NV
NPIs fully relaxed on December 4 th ; no vaccination V1 NPIs fully relaxed on December 4 th ; vaccination schedule as in Figure 1A

V2
NPIs maintained at currently estimated levels then fully relaxed after vaccination of healthcare workers; vaccination schedule as in Figure 1A

V3
NPIs maintained at currently estimated levels then gradually relaxed after vaccination of essential workers; vaccination schedule as in Figure 1A

V4
NPIs strengthened to R0=1.5, then gradually relaxed after vaccination of essential workers; vaccination schedule as in Figure 1A

V5
NPIs maintained at currently estimated levels then fully relaxed upon vaccination of 100 million people; vaccination schedule as in Figure 1A

V6
NPIs strengthened to R0=1.5, then gradually relaxed upon vaccination of 140 million people; vaccination schedule as in Figure 1A SUPPLEMENTARY MATERIAL

The importance of continued non-pharmaceutical interventions during the upcoming SARS-COV-2 vaccination campaign 1 Model Description
The model is a single location Susceptible-Exposed-Infected-Recovered-Vaccinated (SEIRV) compartmental structure run in isolation for each state in the US. We accounted for 5 age groups and 4 population types: healthcare workers (HC), essential workers (EW), individuals with preexisting conditions (PC) and others (O) (see Table S1). This compartmental model is a modification of the structure that our group has used for inference and forecast for multiple infectious diseases, including influenza [Shaman, 2012].
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20248784 doi: medRxiv preprint For each group Si, Ei, Ii, Ui, Vi and Ri represent the susceptible, exposed, infected reported and unreported, vaccinated and recovered populations, the duration of infectious period, Z the latency period, N the population size, ! the ascertainment rate of infection, travel-related importation of SARS-COV-2 into the model domain, ! the vaccination rate, and vaccine (in)effectiveness. We allow the transmission rate to vary through specific age-dependent contact rates !,# between individuals in age group Ni and Nj, such that the transmission term reads Parameter r reflects the decreased probability of transmission for unreported infectious individuals. In the present model, we did not consider waning immunity and the possibility of reinfection.
The model was parametrized based on inference methods described in Section 2, and 100 ensemble projections were simulated in each state for 400 days starting from initial conditions estimated on December 4 th .

Parametrization
Our strategy for defining the distributions of parameters and variables in system (1) is based on the following steps: 1) We estimated the population-level distribution (interquartile range) of the epidemiological parameters in each State with a non-stratified metapopulation model/ EAKF filter framework. Details on the inference procedure can be found in . 2) We combine the population-level estimates with additional data and published estimates to stratify the parameters by age and population type (see Table S2 for details on specific parameters and variables).

3) We initialized system (1) with the stratified distribution of parameters and initial
conditions. For each state, we ran 100 simulations, each with initial conditions and parameters randomly drawn from the estimated distributions. Table S2: Age-and population-specific parameter specifications. Although all parameters and variables are state-specific, we omitted the subscript S=1,,50 for the sake of clarity. Estimated parameters were inferred with the model-inference framework described in   We set $ ! so that the sum over the groups is equal to the estimated $ on Dec 4 th and the relative ratio of infection . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 26, 2020. ; https://doi.org/10.1101/2020.12.23.20248784 doi: medRxiv preprint Nationwide Commercial Laboratory Seroprevalence Survey [CDC] prevalence across age group matches the serological observations: − $ =u ∑ ! ! and ! and ! are the population of age group i in state S and the seroprevalence in state S.
(The same seroprevalence was adopted for different groups of same age). We set initial condition for $ ! , $ ! , $ ! to match the seroprevalence ratio across age groups, the sum over the groups matches the posterior estimates for $ , $ , $ on Dec. 4 th : week after the second dose. We did not account for partial immunity between doses. We assumed that each individual received the second dose exactly 3 (I1) and 4 (I2) weeks after the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 26, 2020. ; first dose. Weekly doses were distributed uniformly over 7 days. Vaccine distribution timeline is detailed in Table S3. Vaccines were distributed according to the following prioritization schedule (doses required and target coverage) 1) Healthcare workers (31 million doses necessary to fully immunize 80%) 2) Essential workers (70 million doses necessary to fully immunize 60%) 3) 65+ with pre-existing conditions: (22.5 million doses necessary to fully immunize 70%) 4) Other 65+ (70%) 5) Adults with pre-existing conditions (70%) 6) Children 1-4 y/o, followed by children 5-17 (60%); note, the vaccines are currently not indicated for children. 7) Other adults (60%)